已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study

塞库金单抗 伊克泽珠单抗 医学 银屑病 阿达木单抗 中止 皮肤病科 回顾性队列研究 银屑病面积及严重程度指数 内科学 银屑病性关节炎 疾病
作者
Ying Li,Jiajing Lu,Xiaoyuan Zhong,Ying-Yuan Yu,Na Yu,Yu Wang,Yonggang Xie,Yangfeng Ding,Yuling Shi
出处
期刊:Clinical, Cosmetic and Investigational Dermatology [Dove Medical Press]
卷期号:Volume 15: 2245-2252 被引量:8
标识
DOI:10.2147/ccid.s387759
摘要

Data pertaining to biologic agents used for treating psoriasis in real-world settings are lacking at present. To compare drug survival at 52 weeks for a range of biologics used to treat psoriasis under real-world conditions.This was a retrospective, single-center, observational study of a cohort of patients diagnosed with plaque psoriasis treated using ixekizumab, secukinumab, guselkumab, or adalimumab between January 2020 and December 2021. Baseline demographic characteristics, duration of psoriasis, and prior biological treatments for all patients were recorded. Drug survival rates were analyzed in different patient groups using Kaplan-Meier curves and Log rank tests.In total, this study included 386 plaque psoriasis patients, of whom 70, 175, 36, and 105 were, respectively, treated using ixekizumab, secukinumab, guselkumab, and adalimumab. Over a 52-week period, the overall cumulative drug survival rates for ixekizumab, secukinumab, guselkumab, and adalimumab were 67.1%, 63.0%, 72.2%, and 37.1%, respectively. Lack of efficacy was the primary cause of discontinuation for these biologic therapies, followed by economic burden and adverse event incidence.These results suggest that guselkumab exhibited superior drug survival, drug survival outcomes for ixekizumab and secukinumab were comparable, and significantly better than those of adalimumab in China. Preventing a loss of drug efficacy represents a primary approach to improving biologic drug survival in psoriasis patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Isabella610关注了科研通微信公众号
1秒前
4秒前
Handa完成签到,获得积分10
6秒前
哟哟哟完成签到,获得积分10
6秒前
凌寻冬发布了新的文献求助10
9秒前
汉堡包应助半圭为璋采纳,获得10
14秒前
daytoy_18完成签到,获得积分10
15秒前
22秒前
怡然发卡发布了新的文献求助10
24秒前
24秒前
25秒前
25秒前
传奇3应助Chaelisa采纳,获得50
28秒前
红炉一点雪完成签到 ,获得积分10
28秒前
顶钻师发布了新的文献求助10
30秒前
Isabella610发布了新的文献求助30
31秒前
milkdrink完成签到,获得积分10
32秒前
34秒前
zhiruo发布了新的文献求助10
34秒前
yyc发布了新的文献求助10
34秒前
wu发布了新的文献求助10
35秒前
脑洞疼应助科研通管家采纳,获得10
36秒前
科研通AI2S应助科研通管家采纳,获得10
36秒前
彭于晏应助科研通管家采纳,获得10
36秒前
科研通AI2S应助科研通管家采纳,获得10
36秒前
乐乐应助科研通管家采纳,获得200
37秒前
SciGPT应助科研通管家采纳,获得10
37秒前
充电宝应助科研通管家采纳,获得10
37秒前
37秒前
37秒前
Jasper应助科研通管家采纳,获得10
37秒前
绵绵完成签到 ,获得积分10
40秒前
充电宝发布了新的文献求助10
42秒前
42秒前
42秒前
milkdrink发布了新的文献求助10
44秒前
戴哈哈发布了新的文献求助10
44秒前
yyc完成签到,获得积分10
45秒前
我心向明月完成签到,获得积分10
48秒前
Chaelisa发布了新的文献求助50
49秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
New China Forges Ahead: Important Documents of the Third Session of the First National Committee of the Chinese People's Political Consultative Conference 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3056349
求助须知:如何正确求助?哪些是违规求助? 2712892
关于积分的说明 7433585
捐赠科研通 2357851
什么是DOI,文献DOI怎么找? 1249112
科研通“疑难数据库(出版商)”最低求助积分说明 606850
版权声明 596195